Literature DB >> 33318204

Identification of novel targets of azithromycin activity against Pseudomonas aeruginosa grown in physiologically relevant media.

Corrie R Belanger1, Amy Huei-Yi Lee1,2, Daniel Pletzer1,3, Bhavjinder Kaur Dhillon1, Reza Falsafi1, Robert E W Hancock4.   

Abstract

Pseudomonas aeruginosa causes severe multidrug-resistant infections that often lead to bacteremia and sepsis. Physiologically relevant conditions can increase the susceptibility of pathogens to antibiotics, such as azithromycin (AZM). When compared to minimal-inhibitory concentrations (MICs) in laboratory media, AZM had a 16-fold lower MIC in tissue culture medium with 5% Mueller Hinton broth (MHB) and a 64-fold lower MIC in this tissue culture medium with 20% human serum. AZM also demonstrated increased synergy in combination with synthetic host-defense peptides DJK-5 and IDR-1018 under host-like conditions and in a murine abscess model. To mechanistically study the altered effects of AZM under physiologically relevant conditions, global transcriptional analysis was performed on P. aeruginosa with and without effective concentrations of AZM. This revealed that the arn operon, mediating arabinosaminylation of lipopolysaccharides and related regulatory systems, was down-regulated in host-like media when compared to MHB. Inactivation of genes within the arn operon led to increased susceptibility of P. aeruginosa to AZM and great increases in synergy between AZM and other antimicrobial agents, indicating that dysregulation of the arn operon might explain increased AZM uptake and synergy in host-like media. Furthermore, genes involved in central and energy metabolism and ribosome biogenesis were dysregulated more in physiologically relevant conditions treated with AZM, likely due to general changes in cell physiology as a result of the increased effectiveness of AZM in these conditions. These data suggest that, in addition to the arn operon, there are multiple factors in host-like environments that are responsible for observed changes in susceptibility.

Entities:  

Keywords:  Pseudomonas aeruginosa; RNA-Seq; antibiotic susceptibility; azithromycin; host-mimicking media

Mesh:

Substances:

Year:  2020        PMID: 33318204      PMCID: PMC7777150          DOI: 10.1073/pnas.2007626117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  Comprehensive transposon mutant library of Pseudomonas aeruginosa.

Authors:  Michael A Jacobs; Ashley Alwood; Iyarit Thaipisuttikul; David Spencer; Eric Haugen; Stephen Ernst; Oliver Will; Rajinder Kaul; Christopher Raymond; Ruth Levy; Liu Chun-Rong; Donald Guenthner; Donald Bovee; Maynard V Olson; Colin Manoil
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-14       Impact factor: 11.205

2.  PhoP-PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance.

Authors:  E L Macfarlane; A Kwasnicka; M M Ochs; R E Hancock
Journal:  Mol Microbiol       Date:  1999-10       Impact factor: 3.501

3.  Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosa.

Authors:  Isabel Pérez-Martínez; Dieter Haas
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 4.  In Vitro Analysis of Pseudomonas aeruginosa Virulence Using Conditions That Mimic the Environment at Specific Infection Sites.

Authors:  J A Colmer-Hamood; N Dzvova; C Kruczek; A N Hamood
Journal:  Prog Mol Biol Transl Sci       Date:  2016-08-08       Impact factor: 3.622

5.  Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances.

Authors:  Irith Wiegand; Kai Hilpert; Robert E W Hancock
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

6.  Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability.

Authors:  Julien M Buyck; Patrick Plésiat; H Traore; F Vanderbist; Paul M Tulkens; Françoise Van Bambeke
Journal:  Clin Infect Dis       Date:  2012-05-09       Impact factor: 9.079

7.  New Mouse Model for Chronic Infections by Gram-Negative Bacteria Enabling the Study of Anti-Infective Efficacy and Host-Microbe Interactions.

Authors:  Daniel Pletzer; Sarah C Mansour; Kelli Wuerth; Negin Rahanjam; Robert E W Hancock
Journal:  mBio       Date:  2017-02-28       Impact factor: 7.867

8.  Microbe Profile: Pseudomonas aeruginosa: opportunistic pathogen and lab rat.

Authors:  Stephen P Diggle; Marvin Whiteley
Journal:  Microbiology       Date:  2020-01       Impact factor: 2.777

9.  Quantitative Framework for Model Evaluation in Microbiology Research Using Pseudomonas aeruginosa and Cystic Fibrosis Infection as a Test Case.

Authors:  Daniel M Cornforth; Frances L Diggle; Jeffrey A Melvin; Jennifer M Bomberger; Marvin Whiteley
Journal:  mBio       Date:  2020-01-14       Impact factor: 7.867

10.  The neglected intrinsic resistome of bacterial pathogens.

Authors:  Alicia Fajardo; Nadia Martínez-Martín; María Mercadillo; Juan C Galán; Bart Ghysels; Sandra Matthijs; Pierre Cornelis; Lutz Wiehlmann; Burkhard Tümmler; Fernando Baquero; José L Martínez
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

View more
  9 in total

1.  Self-Assembly of Antimicrobial Peptoids Impacts Their Biological Effects on ESKAPE Bacterial Pathogens.

Authors:  Josefine Eilsø Nielsen; Morgan Ashley Alford; Deborah Bow Yue Yung; Natalia Molchanova; John A Fortkort; Jennifer S Lin; Gill Diamond; Robert E W Hancock; Håvard Jenssen; Daniel Pletzer; Reidar Lund; Annelise E Barron
Journal:  ACS Infect Dis       Date:  2022-02-17       Impact factor: 5.084

Review 2.  Leveraging laboratory and clinical studies to design effective antibiotic combination therapy.

Authors:  Kathleen Davis; Talia Greenstein; Roberto Viau Colindres; Bree B Aldridge
Journal:  Curr Opin Microbiol       Date:  2021-10-08       Impact factor: 7.934

Review 3.  Expanding the search for small-molecule antibacterials by multidimensional profiling.

Authors:  Karin Ortmayr; Roberto de la Cruz Moreno; Mattia Zampieri
Journal:  Nat Chem Biol       Date:  2022-05-23       Impact factor: 16.174

4.  Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis.

Authors:  Jonah Larkins-Ford; Talia Greenstein; Nhi Van; Yonatan N Degefu; Michaela C Olson; Artem Sokolov; Bree B Aldridge
Journal:  Cell Syst       Date:  2021-08-31       Impact factor: 10.304

5.  Azithromycin: An Underappreciated Quinolone-Sparing Oral Treatment for Pseudomonas aeruginosa Infections.

Authors:  Erlinda R Ulloa; George Sakoulas
Journal:  Antibiotics (Basel)       Date:  2022-04-13

6.  Drosophila immunity: the Drosocin gene encodes two host defence peptides with pathogen-specific roles.

Authors:  M A Hanson; S Kondo; B Lemaitre
Journal:  Proc Biol Sci       Date:  2022-06-22       Impact factor: 5.530

Review 7.  Synergy by Perturbing the Gram-Negative Outer Membrane: Opening the Door for Gram-Positive Specific Antibiotics.

Authors:  Charlotte M J Wesseling; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2022-08-10       Impact factor: 5.578

8.  The Azithromycin Pro-Drug CSY5669 Boosts Bacterial Killing While Attenuating Lung Inflammation Associated with Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus.

Authors:  Anno Saris; Wanhai Qin; Christine C A van Linge; Tom D Y Reijnders; Sandrine Florquin; Michael Burnet; Simon Strass; Alex F de Vos; Tom van der Poll
Journal:  Antimicrob Agents Chemother       Date:  2022-08-16       Impact factor: 5.938

9.  Neutrophil-mediated delivery of the combination of colistin and azithromycin for the treatment of bacterial infection.

Authors:  Jiacong Gao; Xueyan Hu; Congjuan Xu; Mingming Guo; Shouyi Li; Fan Yang; Xiaolei Pan; Fangyu Zhou; Yongxin Jin; Fang Bai; Zhihui Cheng; Zhenzhou Wu; Shuiping Chen; Xinglu Huang; Weihui Wu
Journal:  iScience       Date:  2022-08-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.